The European Medicines Agency (EMA) has granted priority medicines (PRIME) designation to Intellia Therapeutics’ NTLA-2002, an experimental gene-editing therapy…
Articles by Steve Bryson, PhD
A 48-year-old man experienced complete remission from hereditary angioedema (HAE) after undergoing a bone marrow transplant for blood cancer,…
A genetic analysis revealed hereditary angioedema (HAE) was hidden among people with chronic, recurring swelling, but without an apparent…
Enrollment has begun in APeX-P, a Phase 3 trial designed to evaluate the effects of Orladeyo (berotralstat) in up…
Adult and adolescent patients, ages 12 and older, with hereditary angioedema (HAE)Â in Israel can now receive once-daily…
A Japanese woman was diagnosed with a rare case of non-episodic angioedema associated with eosinophilia (NEAE), with remarkably…
Researchers have developed a simple scoring system to help clinicians identify angioedema patients at high or low…
The Phase 2 KOMPLETE clinical trial testing the ability of oral KVD824 to prevent attacks in people with…
KalVista Pharmaceuticals has launched a two-year open-label extension (OLE) study, dubbed KONFIDENT-S, to test the long-term safety of oral…
Regulatory authorities in Saudi Arabia have approved daily Orladeyo (berotralstat) to prevent hereditary angioedema (HAE) attacks in adult…